[{"address1": "11682 El Camino Real", "address2": "Suite 120", "city": "San Diego", "state": "CA", "zip": "92130", "country": "United States", "phone": "858 771 9307", "website": "https://ars-pharma.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.", "fullTimeEmployees": 23, "companyOfficers": [{"maxAge": 1, "name": "Mr. Richard  Lowenthal M.B.A., M.S., MSMSEL", "age": 57, "title": "Founder, President, CEO & Director", "yearBorn": 1966, "fiscalYear": 2023, "totalPay": 2746096, "exercisedValue": 0, "unexercisedValue": 2051778}, {"maxAge": 1, "name": "Dr. Sarina  Tanimoto M.B.A., M.D.", "age": 54, "title": "Co-Founder & Chief Medical Officer", "yearBorn": 1969, "fiscalYear": 2023, "totalPay": 2470993, "exercisedValue": 0, "unexercisedValue": 718122}, {"maxAge": 1, "name": "Mr. Alexander A. Fitzpatrick Esq.", "age": 56, "title": "Chief Legal Officer & Secretary", "yearBorn": 1967, "fiscalYear": 2023, "totalPay": 677145, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Robert  Bell Ph.D.", "title": "Co-Founder & Chief Science Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Kathleen D. Scott CPA", "title": "Chief Financial Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Brian T. Dorsey M.S.", "age": 54, "title": "Chief Operations Officer", "yearBorn": 1969, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Daniel  Relovsky", "title": "Senior Vice President of Marketing", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Harris  Kaplan M.B.A.", "age": 71, "title": "Executive Vice President of Commercial Strategy", "yearBorn": 1952, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Eric  Karas", "age": 50, "title": "Chief Commercial Officer", "yearBorn": 1973, "fiscalYear": 2023, "totalPay": 618614, "exercisedValue": 0, "unexercisedValue": 4320554}, {"maxAge": 1, "name": "Mr. Justin  Chakma", "age": 33, "title": "Chief Business Officer & Secretary", "yearBorn": 1990, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 9, "boardRisk": 10, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 10, "governanceEpochDate": 1727740800, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 16.13, "open": 16.1, "dayLow": 15.9, "dayHigh": 16.39, "regularMarketPreviousClose": 16.13, "regularMarketOpen": 16.1, "regularMarketDayLow": 15.9, "regularMarketDayHigh": 16.39, "forwardPE": -18.811764, "volume": 715519, "regularMarketVolume": 715519, "averageVolume": 1118857, "averageVolume10days": 837160, "averageDailyVolume10Day": 837160, "marketCap": 1550096128, "fiftyTwoWeekLow": 3.38, "fiftyTwoWeekHigh": 16.89, "priceToSalesTrailing12Months": 3100.1921, "fiftyDayAverage": 13.5676, "twoHundredDayAverage": 9.848075, "currency": "USD", "enterpriseValue": 1331512320, "floatShares": 44946977, "sharesOutstanding": 96941600, "sharesShort": 11097485, "sharesShortPriorMonth": 10960219, "sharesShortPreviousMonthDate": 1724976000, "dateShortInterest": 1727654400, "sharesPercentSharesOut": 0.1145, "heldPercentInsiders": 0.23214, "heldPercentInstitutions": 0.65876997, "shortRatio": 10.96, "shortPercentOfFloat": 0.2157, "bookValue": 2.22, "priceToBook": 7.2027025, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -44842000, "trailingEps": -0.47, "forwardEps": -0.85, "enterpriseToRevenue": 2663.025, "enterpriseToEbitda": -23.494, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "SPRY", "underlyingSymbol": "SPRY", "shortName": "ARS Pharmaceuticals, Inc.", "longName": "ARS Pharmaceuticals, Inc.", "firstTradeDateEpochUtc": 1607092200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "d8a743bf-b873-3187-ac17-afe99130ffb3", "gmtOffSetMilliseconds": -14400000, "currentPrice": 15.99, "targetHighPrice": 30.0, "targetLowPrice": 22.0, "targetMeanPrice": 25.67, "targetMedianPrice": 25.0, "recommendationMean": 1.2, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 3, "totalCash": 218744000, "totalCashPerShare": 2.256, "ebitda": -56674000, "totalDebt": 160000, "quickRatio": 32.608, "currentRatio": 32.823, "totalRevenue": 500000, "debtToEquity": 0.074, "revenuePerShare": 0.005, "returnOnAssets": -0.14753, "returnOnEquity": -0.19337, "freeCashflow": -26328000, "operatingCashflow": -44157000, "revenueGrowth": 49.0, "operatingMargins": -30.68, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-10-21"}]